Guotou Securities·2026-04-01 09:41Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 136.15 CNY per share [6][9]. Core Views - The company reported a revenue of 6.67 billion CNY and a net profit attributable to shareholders of 1.13 billion CNY for 2025, representing year-on-year growth of 14.91% and 19.35% respectively [1][2]. - The company is expected to achieve a revenue growth of 19%-22% in 2026 due to continuous order growth and improving operational conditions [2][3]. - The total order backlog reached 1.385 billion USD, a year-on-year increase of 31.65%, with significant growth in orders for chemical and biological macromolecule CDMO services [3]. - The company is actively expanding its production capacity, with plans to increase the total capacity for peptide solid-phase synthesis from 45,000L to 69,000L by the end of 2026 [3]. - The company has a rich pipeline of mid-to-late stage projects, with expectations for multiple commercialized projects in both small molecule CDMO and emerging business sectors in 2026 [4]. Financial Summary - The projected net profits for the company from 2026 to 2028 are 1.40 billion CNY, 1.74 billion CNY, and 2.21 billion CNY, reflecting year-on-year growth rates of 23.8%, 24.3%, and 27.0% respectively [5]. - The company’s earnings per share (EPS) for 2026 is estimated to be 3.89 CNY, with a price-to-earnings (PE) ratio of 35 times, leading to a target price of 136.15 CNY per share [9]. - The company’s revenue is expected to grow from 5.8 billion CNY in 2024 to 12.46 billion CNY in 2028, with a compound annual growth rate (CAGR) of 23.0% [10][11].